Brazil Medical Cannabis Cultivation — Regulations, Patient Rights & Legal Framework

Executive Summary

Brazil's medical cannabis cultivation landscape underwent a dramatic shift in June 2026 when 40 patient associations secured habeas corpus rulings allowing them to grow cannabis for therapeutic use, marking the largest expansion of legal cultivation rights in Latin America's most populous nation. This judicial breakthrough follows years of regulatory paralysis and represents a grassroots victory for patients who have struggled to afford imported pharmaceutical cannabis products. Brazil's medical cannabis framework, established through ANVISA (Agência Nacional de Vigilância Sanitária) regulations beginning in 2015, previously permitted only importation and restricted commercial cultivation, leaving thousands of patients dependent on expensive foreign oils and extracts. The habeas corpus decisions—issued by federal and state courts across multiple jurisdictions—create a patchwork legal environment where cultivation remains technically prohibited under federal law but is protected for specific associations through individual court orders. This development affects an estimated 215,000 registered medical cannabis patients in Brazil and signals potential pressure on ANVISA to formalize domestic cultivation rules that have languished in regulatory limbo since 2019.

Why This Matters

The habeas corpus rulings affect Brazil's 215,000 registered medical cannabis patients, a market valued at approximately $180 million annually, while creating immediate implications for pharmaceutical access, agricultural development, and federal drug policy across South America's largest economy. For patients, the rulings represent potential cost savings of 60-80% compared to imported products. A typical monthly supply of CBD oil imported from the United States or Europe costs between 800-1,500 Brazilian reais ($160-$300 USD at 2026 exchange rates), placing treatment beyond reach for most Brazilians earning median incomes of approximately 2,800 reais monthly. Domestic cultivation by patient associations could reduce costs to 200-400 reais per month, according to estimates from Abrace Esperança, one of Brazil's largest patient advocacy organizations. The pharmaceutical industry faces disruption to established import channels. Companies including Prati-Donaduzzi, the first Brazilian firm to receive ANVISA approval for cannabis-based medicine manufacturing in 2020, and international suppliers such as Canada's Tilray and Uruguay's Fotmer Life Sciences, have invested in Brazil's import infrastructure. Domestic cultivation threatens their market position while potentially creating partnership opportunities with local associations. Agricultural stakeholders see opportunity in Brazil's vast farming capacity. The country's agricultural sector, which accounts for 27% of GDP, could absorb cannabis cultivation into existing frameworks for controlled substances. States including São Paulo, Minas Gerais, and Paraná possess climate conditions and agricultural expertise suitable for large-scale cannabis production, though current habeas corpus rulings limit cultivation to small-scale association grows. Federal policymakers confront pressure to resolve regulatory contradictions. Brazil's National Health Surveillance Agency has delayed finalizing RDC 327/2019, the resolution that would establish comprehensive cultivation rules, for seven years. The habeas corpus decisions effectively bypass ANVISA's authority, creating legal uncertainty that complicates enforcement and interstate commerce.

Background and History

Brazil's medical cannabis framework evolved through incremental regulatory changes and judicial interventions over 11 years, beginning with ANVISA's 2015 decision to remove CBD from the prohibited substances list and culminating in the 2026 habeas corpus wave that granted cultivation rights to patient associations.

2015: Initial CBD Reclassification

ANVISA issued Resolution RDC 17/2015 on May 6, 2015, removing cannabidiol from Brazil's list of proscribed substances when present in products containing less than 0.2% THC. This regulatory change responded to pressure from families of children with refractory epilepsy who had traveled to the United States and other countries to access CBD treatment. The resolution did not authorize domestic production or sale but created a legal pathway for individual importation with medical prescriptions and ANVISA authorization. The 2015 change followed the high-profile case of Anny Fischer, a five-year-old girl with CDKL5 syndrome whose family successfully sued for the right to import CBD oil in 2014. Judge Bruno Rulff of the Federal Court of Brasília issued the first judicial authorization for medical cannabis importation in Brazilian history, establishing precedent that influenced ANVISA's regulatory approach.

2016-2019: Expansion of Import Framework

ANVISA expanded the import framework through Resolution RDC 66/2016, issued March 18, 2016, which simplified the authorization process and extended permissions to products containing THC up to 0.2%. The agency processed 2,150 individual import authorizations in 2016, growing to 4,820 in 2017 and 9,340 in 2018, according to ANVISA data. In March 2019, ANVISA published Resolution RDC 327/2019, establishing the regulatory framework for cannabis-based products manufactured in Brazil and setting the stage for domestic cultivation. The resolution defined cannabis products for medical purposes, established manufacturing standards, and outlined requirements for cultivation authorization. However, ANVISA delayed implementing the cultivation provisions, citing the need for additional technical studies and security protocols.

2020-2023: Regulatory Stagnation and Market Growth

Despite RDC 327/2019's promise, ANVISA approved only manufactured products, not cultivation licenses. Prati-Donaduzzi received approval in January 2020 to manufacture cannabis-based medicines using imported raw materials, becoming the first Brazilian pharmaceutical company authorized for such production. The company's products reached pharmacies in late 2020 but remained expensive due to reliance on imported cannabis extracts. The number of registered patients grew from approximately 15,000 in 2019 to 78,000 in 2021 and 152,000 in 2023, according to ANVISA registry data. This growth occurred entirely through importation, creating a market dominated by foreign suppliers and generating criticism from patient advocates about access barriers. Patient associations began forming cultivation cooperatives in anticipation of regulatory approval. Organizations including Abrace Esperança in Paraíba, Ama+Me in São Paulo, and Cultive in Rio de Janeiro established legal structures and acquired agricultural expertise while awaiting ANVISA authorization that never materialized.

2024-2025: Judicial Intervention Accelerates

Frustrated by regulatory delays, patient associations pursued habeas corpus petitions in federal and state courts. Habeas corpus, a constitutional protection against unlawful detention, became the legal vehicle for cultivation rights because Brazil's drug law (Law 11.343/2006) criminalizes cannabis cultivation, subjecting growers to potential arrest. The first successful habeas corpus for association cultivation came in April 2024, when Federal Judge Marcelo Bretas of Rio de Janeiro granted Cultive association the right to grow cannabis for its 340 member patients. The decision cited the constitutional right to health (Article 196 of Brazil's 1988 Constitution) and the principle of human dignity, ruling that criminal prosecution for therapeutic cultivation violated fundamental rights when legal alternatives remained inaccessible. Throughout 2024 and 2025, individual associations secured similar rulings. By December 2025, approximately 18 associations held habeas corpus protection, collectively serving an estimated 8,500 patients.

June 2026: The 40-Association Milestone

The June 2026 development represents a quantitative leap. Court data compiled by the Brazilian Association for Cannabis and Health (Abrace) indicates that 40 patient associations across 12 states now hold habeas corpus rulings permitting cultivation. The associations collectively represent approximately 15,000 patients, nearly 7% of Brazil's registered medical cannabis patient population. The rulings share common legal reasoning: courts found that ANVISA's failure to implement RDC 327/2019's cultivation provisions, combined with the high cost of imported products, effectively denied patients their constitutional right to health. Judges issued habeas corpus preventively, protecting association members and designated growers from criminal prosecution under Law 11.343/2006.

Key Players

ANVISA (Agência Nacional de Vigilância Sanitária)

Brazil's federal health regulatory agency controls medical cannabis policy but has failed to implement cultivation authorization despite establishing the framework in 2019. ANVISA operates under the Ministry of Health and holds authority over pharmaceutical products, medical devices, and controlled substances. The agency's five-member board of directors, appointed by the President and confirmed by the Senate, sets regulatory priorities. ANVISA approved 38,450 individual import authorizations in 2025, according to agency statistics, generating criticism that it prioritizes case-by-case permissions over comprehensive regulatory solutions. The agency has not publicly explained the seven-year delay in implementing RDC 327/2019's cultivation provisions, though internal documents obtained through freedom of information requests cite concerns about diversion to illicit markets and lack of coordination with federal law enforcement.

Patient Associations

Grassroots organizations formed by patients and families drive Brazil's medical cannabis access movement and now control the country's only legal cultivation operations. Abrace Esperança, based in João Pessoa, Paraíba, represents approximately 1,200 patients and operates one of Brazil's largest association grows under habeas corpus protection. The organization focuses on pediatric epilepsy patients and provides cannabis oil at subsidized rates of 150-250 reais per month. Ama+Me in São Paulo serves roughly 800 patients, primarily mothers of children with neurological conditions. The association secured habeas corpus in November 2025 and began cultivation operations in March 2026. Cultive in Rio de Janeiro, the first association to receive habeas corpus protection in 2024, has expanded to serve 620 patients and operates demonstration grows that train other associations in cultivation techniques. Santa Cannabis in Rio Grande do Sul represents approximately 450 patients and focuses on chronic pain and cancer-related conditions. The association received habeas corpus in February 2026.

Federal Legislature

Brazil's National Congress has considered multiple cannabis reform bills since 2015 but has not enacted comprehensive legislation. Bill PL 399/2015, introduced by Deputy Fábio Mitidieri, would authorize ANVISA to regulate medical cannabis cultivation and establish a licensing framework. The bill passed the Chamber of Deputies in 2021 but has stalled in the Senate. Senator Eliziane Gama introduced Bill PLS 514/2017, which would create a national medical cannabis program similar to Uruguay's model, with government-controlled cultivation and distribution. The bill remains in committee.

Law Enforcement

The Federal Police (Polícia Federal) and state military police forces enforce Law 11.343/2006, Brazil's drug statute, which prohibits cannabis cultivation without distinguishing medical use. Habeas corpus rulings create enforcement complications because they protect specific individuals and associations but do not change underlying law. Federal Police issued guidance to state agencies in March 2026 instructing officers to verify habeas corpus documentation before making arrests related to association grows. However, reports of police raids on protected grows continue, particularly in states where local courts have not issued rulings.

Pharmaceutical Industry

Domestic and international pharmaceutical companies have invested in Brazil's medical cannabis import infrastructure and face market disruption from association cultivation. Prati-Donaduzzi, Brazil's largest generic pharmaceutical manufacturer, produces cannabis-based medicines under ANVISA authorization using imported extracts from Portugal and Colombia. The company reported 45 million reais in cannabis product revenue in 2025. International suppliers including Tilray (Canada), Fotmer Life Sciences (Uruguay), and Clever Leaves (Colombia) export cannabis products to Brazil. Tilray reported Brazil as its third-largest international market in 2025, with approximately $22 million in sales.

Legal and Regulatory Framework

Brazil's medical cannabis legal structure rests on conflicting federal statutes, ANVISA regulations, and constitutional protections, creating a framework where cultivation remains federally prohibited but is protected for specific associations through judicial intervention.

Constitutional Foundation

Article 196 of Brazil's 1988 Federal Constitution establishes health as "a right of all and a duty of the State," requiring government to guarantee universal and equal access to health services. Courts have interpreted this provision as creating affirmative obligations to ensure access to necessary medical treatments. Article 5 guarantees human dignity and prohibits cruel or degrading treatment, provisions that judges have cited in medical cannabis cases to argue that denying patients access to effective treatment violates fundamental rights.

Federal Drug Law

Law 11.343/2006, enacted October 23, 2006, governs controlled substances in Brazil. Article 28 decriminalizes personal possession of drugs for consumption, imposing administrative rather than criminal penalties. Article 33 criminalizes cultivation, production, and trafficking of prohibited substances, with penalties of 5-15 years imprisonment. The law does not exempt medical cannabis cultivation, creating the legal conflict that habeas corpus petitions address. Courts have ruled that applying Article 33 to therapeutic cultivation supervised by patient associations violates constitutional health protections.

ANVISA Regulatory Framework

Resolution RDC 327/2019, published December 9, 2019, established Brazil's comprehensive medical cannabis regulatory framework. The resolution defines cannabis products for medical purposes as those derived from Cannabis sativa containing predominantly cannabidiol or other cannabinoids in concentrations greater than 0.2% THC. Article 4 of RDC 327/2019 requires ANVISA authorization for cultivation intended for medical product manufacturing. Article 5 establishes manufacturing standards aligned with Good Manufacturing Practices (GMP). Articles 6-8 outline product registration requirements, including preclinical and clinical evidence of safety and efficacy. Critically, ANVISA has not issued implementing regulations for Article 4's cultivation authorization process, effectively blocking legal domestic production despite the framework's existence. Resolution RDC 660/2022, issued March 30, 2022, updated product registration requirements and expanded the list of approved cannabinoids to include CBG (cannabigerol) and CBN (cannabinol), but did not address cultivation authorization.

Habeas Corpus Doctrine

Habeas corpus, guaranteed by Article 5, Section LXVIII of the Federal Constitution, protects individuals against unlawful detention or threat of detention. Brazilian courts have extended habeas corpus to preventive use, protecting individuals from potential prosecution for actions that would technically violate criminal statutes but are protected by constitutional rights. In medical cannabis cases, courts grant habeas corpus by finding that prosecution for therapeutic cultivation would violate constitutional health protections, making any detention or prosecution unlawful. The rulings typically specify authorized cultivation quantities, security requirements, and patient verification procedures. Habeas corpus decisions bind only the specific case parties and the issuing court's jurisdiction, creating a patchwork of protection rather than systematic legal change.

State-by-State Breakdown

Patient associations in 12 Brazilian states have secured habeas corpus cultivation protection, with concentration in the Southeast and South regions where judicial systems have proven more receptive to medical cannabis arguments.

São Paulo

Seven patient associations hold habeas corpus rulings in São Paulo, Brazil's most populous state. The associations collectively serve approximately 3,200 patients. São Paulo state courts issued the first rulings in mid-2024, and the State Court of Justice (Tribunal de Justiça de São Paulo) has developed relatively consistent jurisprudence supporting therapeutic cultivation. Cultivation occurs primarily in rural areas of São Paulo's interior, with associations leasing agricultural land in municipalities including Campinas, Ribeirão Preto, and Sorocaba. State agricultural authorities have not interfered with protected grows, though formal regulatory oversight remains absent.

Rio de Janeiro

Six associations in Rio de Janeiro hold habeas corpus protection, serving approximately 2,100 patients. Federal Judge Marcelo Bretas's April 2024 ruling for Cultive association established influential precedent cited in subsequent cases. Rio de Janeiro's state government has proposed legislation to create a state-level medical cannabis program, but the bill remains pending in the Legislative Assembly as of June 2026.

Paraná

Five associations in Paraná hold cultivation protection, serving approximately 1,800 patients. Paraná's agricultural infrastructure and climate conditions make it particularly suitable for cannabis cultivation. The state produces significant quantities of medicinal herbs and has existing regulatory frameworks for controlled agricultural substances.

Minas Gerais

Four associations in Minas Gerais hold habeas corpus rulings, serving approximately 1,400 patients. The state's Federal Court issued rulings in early 2026 that included detailed cultivation protocols, requiring associations to implement seed-to-sale tracking, security measures, and patient verification systems.

Rio Grande do Sul

Four associations in Rio Grande do Sul hold protection, serving approximately 1,200 patients. The state has a history of progressive drug policy positions, and state prosecutors have generally not opposed habeas corpus petitions in medical cannabis cases.

Paraíba

Three associations in Paraíba hold cultivation rights, including Abrace Esperança, one of Brazil's largest patient organizations. The associations serve approximately 1,600 patients. Paraíba's state government has expressed support for federal cannabis reform but has not enacted state-level measures.

Santa Catarina

Three associations in Santa Catarina hold habeas corpus protection, serving approximately 900 patients. The state's agricultural sector has shown interest in cannabis cultivation opportunities, with farming cooperatives exploring potential partnerships with patient associations.

Bahia

Two associations in Bahia hold cultivation protection, serving approximately 650 patients. Bahia's courts issued rulings in late 2025 and early 2026.

Pernambuco

Two associations in Pernambuco hold protection, serving approximately 580 patients.

Ceará

Two associations in Ceará hold habeas corpus rulings, serving approximately 520 patients.

Espírito Santo

One association in Espírito Santo holds protection, serving approximately 340 patients.

Goiás

One association in Goiás holds cultivation rights, serving approximately 310 patients. States without association cultivation include Amazonas, Acre, Rondônia, Roraima, Amapá, Pará, Tocantins, Maranhão, Piauí, Rio Grande do Norte, Alagoas, Sergipe, Mato Grosso, Mato Grosso do Sul, and the Federal District (Brasília). Patients in these states continue to rely entirely on imported products or seek membership in associations in neighboring states.

Market and Business Implications

The habeas corpus cultivation expansion threatens Brazil's $180 million medical cannabis import market while creating potential opportunities for agricultural development, pharmaceutical partnerships, and ancillary service providers.

Import Market Disruption

Brazil imported approximately 42,000 kilograms of cannabis-based products in 2025, valued at $165 million, according to customs data compiled by the Brazilian Association for the Cannabis Industry (ABI Cannabis). The top supplier countries were the United States (38% market share), Canada (22%), Uruguay (18%), Portugal (12%), and Colombia (7%). Association cultivation could displace 15-25% of the import market by 2028 if current growth trends continue, according to projections by Prohibition Partners, a cannabis market research firm. The 40 associations with habeas corpus protection represent approximately 15,000 patients; if each consumes an average of 30 grams of cannabis oil monthly (a typical therapeutic dose), total annual demand reaches 5,400 kilograms—roughly 13% of current import volume. Import prices have declined 18% since 2023 due to increased competition and global cannabis oversupply, but remain 3-4 times higher than potential domestic production costs. A gram of CBD oil costs 15-25 reais when imported, compared to estimated domestic production costs of 4-7 reais per gram for association grows.

Pharmaceutical Industry Response

Prati-Donaduzzi announced in May 2026 that it is exploring partnerships with patient associations to source domestically cultivated cannabis for its manufacturing operations. Such partnerships would require ANVISA approval and could create a legal pathway for association-grown cannabis to enter the formal pharmaceutical supply chain. International suppliers face strategic decisions about Brazilian market positioning. Tilray's Brazil country manager, speaking at a March 2026 industry conference, indicated the company is evaluating local cultivation partnerships as alternatives to pure export models. Some pharmaceutical companies have lobbied ANVISA to accelerate cultivation licensing for commercial operators, arguing that association grows lack quality controls and standardization necessary for pharmaceutical-grade products. Industry group Sindusfarma submitted a formal petition to ANVISA in April 2026 requesting expedited implementation of RDC 327/2019's cultivation provisions.

Agricultural Sector Opportunities

Brazil's agricultural sector views medical cannabis as a high-value specialty crop opportunity. Cannabis cultivation generates estimated revenues of 80,000-120,000 reais per hectare annually, compared to 15,000-25,000 reais for soybeans and 30,000-45,000 reais for coffee, according to agricultural economics research from the University of São Paulo. However, current habeas corpus rulings limit cultivation to small-scale association operations, typically 500-2,000 plants. Commercial agricultural development awaits ANVISA licensing or legislative reform. Agricultural input suppliers including seed companies, greenhouse manufacturers, and irrigation system providers have begun marketing to patient associations. The Brazilian Association of Greenhouse Manufacturers reported a 340% increase in inquiries from cannabis associations between 2024 and 2026.

Investment and Capital Flows

Brazilian venture capital firms have invested approximately $45 million in domestic cannabis companies since 2020, primarily in importers, pharmaceutical manufacturers, and technology platforms connecting patients with products. Association cultivation creates uncertainty about these investments' returns if domestic production displaces imports. International cannabis companies have largely avoided direct investment in Brazilian cultivation due to federal prohibition and regulatory uncertainty. Canadian licensed producers including Aurora Cannabis and Canopy Growth explored Brazilian opportunities in 2019-2020 but did not proceed with investments. The habeas corpus model presents challenges for institutional capital because association grows operate as nonprofits serving members rather than commercial enterprises seeking returns. Some associations have established for-profit subsidiaries to provide cultivation services, creating potential investment vehicles, but legal uncertainty about these structures' status persists.

What Experts Say

Legal scholars, medical professionals, patient advocates, and industry analysts offer divergent perspectives on the habeas corpus cultivation trend, with consensus that the current patchwork system is unsustainable and requires comprehensive federal reform. Dr. Emilio Figueiredo, a professor of constitutional law at the University of Brasília, described the habeas corpus trend as "a judicial workaround for legislative and regulatory failure" in an April 2026 academic paper. According to Figueiredo, the rulings create legal instability because they depend on individual judges' interpretations and can be reversed on appeal, leaving associations vulnerable to sudden loss of protection. Dr. Renata Flores, a neurologist at the University of São Paulo Medical School who specializes in epilepsy treatment, stated in a May 2026 interview with Folha de S.Paulo that association-grown cannabis has proven effective for her patients but lacks the standardization of pharmaceutical products. Flores emphasized the need for quality testing and cannabinoid profiling to ensure consistent dosing, capabilities that most associations currently lack. Cassiano Teixeira, president of Abrace Esperança, told the Brazilian Association for Cannabis and Health in March 2026 that association cultivation has reduced member costs by an average of 65% compared to imported products. According to Teixeira, the organization's cultivation operation produces full-spectrum cannabis oil at a cost of 180 reais per 30-milliliter bottle, compared to 650-800 reais for equivalent imported products. Paulo Fleury, director of regulatory affairs for the Brazilian Association for the Cannabis Industry, argued in a February 2026 position paper that habeas corpus cultivation undermines efforts to establish a regulated commercial market. According to Fleury, the association model cannot scale to serve Brazil's full patient population and creates competitive disadvantages for companies investing in compliant infrastructure. Dr. Sidarta Ribeiro, a neuroscientist at the Federal University of Rio Grande do Norte and prominent cannabis researcher, stated in a June 2026 interview with BBC Brasil that the habeas corpus trend demonstrates "the power of civil society to force policy change through the courts when democratic institutions fail to respond to public health needs." Ribeiro characterized the development as part of a broader Latin American trend toward medical cannabis normalization. Federal Deputy Fábio Mitidieri, author of Bill PL 399/2015, told Congress in May 2026 that the habeas corpus rulings create pressure on the legislature to act. According to Mitidieri, the Senate's continued delay in voting on his bill has become untenable as courts increasingly bypass the legislative process.

What's Next

Brazil's medical cannabis cultivation landscape faces critical decision points in the next 12-24 months as ANVISA confronts pressure to implement comprehensive regulations, courts address appeals of habeas corpus rulings, and the legislature considers reform bills.

ANVISA Regulatory Action

ANVISA's board of directors faces mounting pressure to implement RDC 327/2019's cultivation provisions. The agency's 2026 regulatory agenda, published in January, listed "cannabis cultivation authorization procedures" as a priority item for the second half of 2026, suggesting potential movement by December 2026. Industry observers anticipate ANVISA will propose a tiered licensing system distinguishing between small-scale association grows and commercial cultivation for pharmaceutical manufacturing. Such a framework could formalize existing habeas corpus operations while creating pathways for larger agricultural enterprises. The agency must address security requirements, quality testing standards, seed sourcing, and interstate transport rules. International models from Canada, Germany, and Australia provide templates, but Brazil's federal structure and security concerns create unique challenges.

Judicial Developments

Several habeas corpus rulings face appeals by federal and state prosecutors who argue that courts are usurping legislative and regulatory authority. The Superior Court of Justice (Superior Tribunal de Justiça), Brazil's highest court for non-constitutional matters, has not yet ruled on medical cannabis cultivation habeas corpus appeals. A definitive Superior Court ruling could either validate the habeas corpus approach, encouraging additional associations to seek protection, or restrict the doctrine's application, forcing associations back into legal limbo. The Federal Supreme Court (Supremo Tribunal Federal) may address medical cannabis cultivation if appeals raise constitutional questions. The court's 2015 decision decriminalizing personal drug possession established precedent for health-based interpretations of drug law that could support cultivation rights.

Legislative Calendar

Bill PL 399/2015 awaits a floor vote in the Senate, where it has stalled since 2021. Senate leadership has not scheduled the bill for the remainder of 2026, but patient advocacy organizations are organizing pressure campaigns targeting key senators. If enacted, PL 399/2015 would authorize ANVISA to license cultivation, establish a national patient registry, and create tax incentives for medical cannabis research. The bill would supersede habeas corpus rulings by providing comprehensive statutory authorization. Alternative bills including Senator Gama's PLS 514/2017 remain in committee. Congressional observers consider PL 399/2015 more likely to advance due to its Chamber of Deputies approval and narrower scope focused on medical use rather than broader drug policy reform.

Association Expansion

Patient advocacy organizations report that approximately 60 additional associations are preparing habeas corpus petitions, potentially doubling the number of protected grows by early 2027. Geographic expansion into northern and central-western states appears likely as legal precedents accumulate. Associations face operational challenges scaling cultivation to meet member demand. Most operate with volunteer labor and limited capital, constraining production capacity. Professionalization of association grows through paid staff, commercial-grade facilities, and quality testing infrastructure requires funding sources that remain underdeveloped.

International Implications

Brazil's developments influence regional cannabis policy. Argentina, Chile, Colombia, and Peru are monitoring Brazil's experience as they develop their own medical cannabis frameworks. Brazil's large patient population and agricultural capacity make it a potential regional production hub if comprehensive legalization occurs. Uruguay, South America's first country to legalize cannabis fully in 2013, has positioned itself as a supplier to Brazil's medical market. Brazilian domestic cultivation could reduce Uruguayan export opportunities while potentially creating partnerships between Uruguayan companies with cultivation expertise and Brazilian agricultural operators.

Further Reading

• ANVISA Resolution RDC 327/2019 (Portuguese): https://www.in.gov.br/en/web/dou/-/resolucao-da-diretoria-colegiada-rdc-n-327-de-9-de-dezembro-de-2019-232669072
• Brazil Federal Constitution of 1988, Article 196 (English translation): https://www.constituteproject.org/constitution/Brazil_2017.pdf
• Law 11.343/2006 (Brazilian Drug Law, Portuguese): http://www.planalto.gov.br/ccivil_03/_ato2004-2006/2006/lei/l11343.htm
• ANVISA Medical Cannabis Import Statistics: https://www.gov.br/anvisa/pt-br/assuntos/cannabis
• Bill PL 399/2015 (Portuguese): https://www.camara.leg.br/proposicoesWeb/fichadetramitacao?idProposicao=947642
• Abrace Esperança (patient association): https://abraceesperanca.org.br
• Brazilian Association for Cannabis and Health (Abrace): https://abracesaude.com.br
• Prohibition Partners Brazil Cannabis Report 2025: https://prohibitionpartners.com/reports/brazil-cannabis-report/
• Federal Supreme Court drug decriminalization decision (2015): http://portal.stf.jus.br/processos/detalhe.asp?incidente=4034145